DMDougald M. Monroe

Dougald M. Monroe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dougald M. Monroe has a total of 385 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Factor V is an anticoagulant of the extrinsic pathway of coagulation and modifier of thrombin generation in hemophilia A

    by Megan Jewell, Christine H. Baird, Dianne Thornhill, Zaina Ashour, Alexandra Riley Bernal, Julie Peterson, Rachel Blomberg, Chelsea M Magin, Alan E Mast, Marilyn J. Manco-Johnson, et al.

    Factor V (FV) links procoagulant amplification to anticoagulant feedback, but how FV limits tissue factor-initiated coagulation are not fully defined. We hypothesized that procofactor FV downregulates factor X (FX) activation by tissue factor:factor VIIa (TF:FVIIa), independently of tissue factor pathway inhibitor α (TFPIα), and that this mechanism is especially important in hemophilia. Thrombin generation was measured in FV/FVIII‑immunodepleted plasma and synthetic plasma while titrating FV, with TFPIα removed, blocked, or re-added. TF:FVIIa activation of FX was measured on phosphatidylserine‑containing or phosphatidylserine‑free liposomes with antibodies against the FV light chain and C2 domain. FV and TFPIα levels modulated thrombin generation in plasma from people with hemophilia A. In TF‑initiated coagulation lacking TFPIα, thrombin generation peaked at 2 nM FV and decreased as FV increased; at 20 nM FV (normal concentration), peak thrombin and thrombin generation rate were reduced by up to 50-80%, with larger effects at low FVIII. In purified TF:FVIIa assays, FV reduced FX activation by ~80% at physiologic concentration and inhibited FX activation on TF-expressing fibroblasts. Increasing PS content enhanced FX activation and increased the FV-sensitive component, while blocking the FV light chain or C2 domain partially relieved inhibition. In hemophilia A plasma, higher FV was associated with longer lag time and time-to-peak, and lower peak thrombin independent of TFPIα. Thus, FV is an endogenous anticoagulant that inhibits TF-initiated coagulation by limiting FX activation by TF:FVIIa through a membrane-dependent mechanism. This mechanism refines models of coagulation initiation and may help explain how FV variation contributes to bleeding and thrombosis.

  • Open Access

    Addressing the pathophysiology of venous thrombosis and chronic kidney disease in sickle cell trait using a mouse model

    by Fatima Trebak, Mohammad O. Sako, Steven P. Grover, Karnsasin Seanoon, Izabela Pawlinski, Chatphatai Moonla, Michael W. Henderson, Vimal K. Derebail, Dougald M. Monroe, Patrick Ellsworth, et al.

    Sickle cell trait (SCT) is present in participants who possess a single copy of the βS-globin gene mutation. Although most affected individuals are asymptomatic, SCT is a well-established risk factor for venous thrombosis and renal complications, including chronic and end-stage kidney disease. After prolonged hypoxia, SCT red blood cells (RBCs) can undergo sickling, and hypoxia-mediated RBC sickling can be enhanced by cellular dehydration, hyperosmolarity, and/or acidosis. Some or all of these conditions may be encountered in the nidus of venous thrombi and in the medulla of the kidney. We sought to determine whether Townes sickle trait (AS) mice develop kidney dysfunction and manifest enhanced venous thrombosis. We demonstrated that the harsh environment within the inner medulla induces RBC sickling in vitro and in vivo and is associated with kidney-related pathologies, including impaired urinary concentration, albuminuria, and declining renal function, closely mimicking those seen in human SCT. In the inferior vena cava model of venous thrombosis, extreme and prolonged hypoxia in the core of RBC-rich venous thrombi resulted in irreversible RBC sickling and larger clots in Townes AS mice than AA controls (littermates expressing hemoglobin A only). Our results support the use of Townes AS mice in future studies investigating mechanisms of venous thrombosis and chronic kidney disease in SCT.


  • Blood coagulation factor IX: structural insights impacting hemophilia B therapy

    by Mettine H. A. Bos, Rianne E. van Diest, Dougald M. Monroe

    Coagulation factor IX plays a central role in hemostasis through interaction with factor VIIIa to form a factor X–activating complex at the site of injury. The absence of factor IX activity results in the bleeding disorder hemophilia B. This absence of activity can arise either from a lack of circulating factor IX protein or mutations that decrease the activity of factor IX. This review focuses on analyzing the structure of factor IX with respect to molecular mechanisms that are at the basis of factor IX function. The proteolytic activation of factor IX to form activated factor IX(a) and subsequent structural rearrangements are insufficient to generate the fully active factor IXa. Multiple specific interactions between factor IXa, the cofactor VIIIa, and the physiological substrate factor X further alter the factor IXa structure to achieve the full enzymatic activity of factor IXa. Factor IXa also interacts with inhibitors, extravascular proteins, and cellular receptors that clear factor IX(a) from the circulation. Hemophilia B is treated by replacement of the missing factor IX by plasma-derived protein, a recombinant bioequivalent, or via gene therapy. An understanding of how the function of factor IX is tied to structure leads to modified forms of factor IX that have increased residence time in circulation, higher functional activity, protection from inhibition, and even activity in the absence of factor VIIIa. These modified forms of factor IX have the potential to significantly improve therapy for patients with hemophilia B.


  • Open Access

    A new look at TFPI inhibition of factor X activation

    by Fabian Santiago, Amandeep Kaur, Shannon Bride, Dougald Monroe, Karin Leiderman, Suzanne Sindi

    Blood coagulation is a vital physiological process involving a complex network of biochemical reactions, which converge to form a blood clot that repairs vascular injury. This process unfolds in three phases: initiation, amplification, and propagation, ultimately leading to thrombin formation. Coagulation begins when tissue factor (TF) is exposed on an injured vessel’s wall. The first step is when activated factor VII (VIIa) in the plasma binds to TF, forming complex TF:VIIa, which activates factor X. Activated factor X (Xa) is necessary for coagulation, so the regulation of its activation is crucial. Tissue Factor Pathway Inhibitor (TFPI) is a critical regulator of the initiation phase as it inhibits the activation of factor X. While previous studies have proposed two pathways—direct and indirect binding—for TFPI’s inhibitory role, the specific biochemical reactions and their rates remain ambiguous. Many existing mathematical models only assume an indirect pathway, which may be less effective under physiological flow conditions. In this study, we revisit datasets from two experiments focused on activated factor X formation in the presence of TFPI. We employ an adaptive Metropolis method for parameter estimation to reinvestigate a previously proposed biochemical scheme and corresponding rates for both inhibition pathways. Our findings show that both pathways are essential to replicate the static experimental results. Previous studies have suggested that flow itself makes a significant contribution to the inhibition of factor X activation. We added flow to this model with our estimated parameters to determine the contribution of the two inhibition pathways under these conditions. We found that direct binding of TFPI is necessary for inhibition under flow. The indirect pathway has a weaker inhibitory effect due to removal of solution phase inhibitory complexes by flow.


  • Stopping the bleed when platelets don’t stick

    by Ammon M. Fager, Dougald M. Monroe

  • Open Access

    Protease: Serpin complexes to assess contact system and intrinsic pathway activation

    by Michael W. Henderson, Denis F. Noubouossie, Anton Ilich, Kathy J. Wilson, Rafal Pawlinski, Dougald M. Monroe, Nigel S. Key


  • VWF (von Willebrand Factor) Is Not Required for Red Blood Cell Retention in Clots in Mice

    by Lori A. Holle, Dougald M. Monroe, Alisa S. Wolberg

    Download figure Download PowerPoint


  • Open Access

    EPCR knockout: inflaming the discussion

    by Dougald Monroe, Maureane Hoffman

    In this issue of Blood, Magisetty et al provide some surprising results from their studies of the role of endothelial protein C receptor (EPCR) in hemophilic arthropathy. There is a rationale for studying EPCR in hemophilia. It is well recognized that EPCR promotes the activation of protein C (PC) to activated PC (aPC) on endothelial surfaces. The aPC has antithrombotic effects by inactivating factor Va (FVa) on nearby endothelial surfaces. Like aPC, activated coagulation FVIIa can also bind to EPCR. Pavani et al showed that binding to EPCR enhances the hemostatic effect of FVIIa in a mouse hemophilia model, when assayed as ferric chloride–induced thrombosis. The Rao group showed that hemostatic levels of FVIIa displace PC from EPCR, and blockade of EPCR reduces the level of FVIIa needed for hemostasis in a saphenous vein bleeding assay. However, they reported that EPCR blockade by itself did not reduce the severity of bleeding in hemophilic mice. They concluded that downregulation of aPC generation is the major mechanism by which FVIIa interaction with EPCR contributes to the hemostatic effect of FVIIa in hemophilia.


  • Open Access

    Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways

    by Denis F. Noubouossie, Michael W. Henderson, Micah Mooberry, Anton Ilich, Patrick Ellsworth, Mark Piegore, Sarah C. Skinner, Rafal Pawlinski, Ian Welsby, Thomas Renné, et al.

    Storage lesion–induced, red cell–derived microvesicles (RBC-MVs) propagate coagulation by supporting the assembly of the prothrombinase complex. It has also been reported that RBC-MVs initiate coagulation via the intrinsic pathway. To elucidate the mechanism(s) of RBC-MV–induced coagulation activation, the ability of storage lesion–induced RBC-MVs to activate each zymogen of the intrinsic pathway was assessed in a buffer system. Simultaneously, the thrombin generation (TG) assay was used to assess their ability to initiate coagulation in plasma. RBC-MVs directly activated factor XII (FXII) or prekallikrein, but not FXI or FIX. RBC-MVs initiated TG in normal pooled plasma and in FXII- or FXI-deficient plasma, but not in FIX-deficient plasma, suggesting an alternate pathway that bypasses both FXII and FXI. Interestingly, RBC-MVs generated FIXa in a prekallikrein-dependent manner. Similarly, purified kallikrein activated FIX in buffer and initiated TG in normal pooled plasma, as well as FXII- or FXI-deficient plasma, but not FIX-deficient plasma. Dual inhibition of FXIIa by corn trypsin inhibitor and kallikrein by soybean trypsin inhibitor was necessary for abolishing RBC-MV–induced TG in normal pooled plasma, whereas kallikrein inhibition alone was sufficient to abolish TG in FXII- or FXI-deficient plasma. Heating RBC-MVs at 60°C for 15 minutes or pretreatment with trypsin abolished TG, suggesting the presence of MV-associated proteins that are essential for contact activation. In summary, RBC-MVs activate both FXII and prekallikrein, leading to FIX activation by 2 independent pathways: the classic FXIIa-FXI-FIX pathway and direct kallikrein activation of FIX. These data suggest novel mechanisms by which RBC transfusion mediates inflammatory and/or thrombotic outcomes.